title: Targeted therapy for gastric cancer: molecular pathways and ongoing investigations.
abstract: Gastric cancer is currently the second leading cause of worldwide cancer mortality. Ongoing collaborative sequencing efforts have highlighted recurrent somatic genomic aberrations in gastric cancer, however, despite advances in characterizing the genomic landscape, there have been few advances in patient outcomes. Prognosis remains poor with a median overall survival of 12 months for advanced disease. The improved survival with trastuzumab, and more recently ramucirumab, underscore the promise of targeted and biologic therapies and the importance of molecular tumor characterization in gastric cancer. Here we review the most frequent actionable alterations in gastric cancer and highlight ongoing clinical investigations attempting to translate biologic understanding into improved clinical outcomes.
authors.affiliation: University of California Irvine, Department of Medicine, Orange, CA, USA.
authors.forename: Wei
authors.initials: W
authors.lastname: Yang
authors.affiliation: University of California Irvine, Department of Medicine, Orange, CA, USA.
authors.forename: Alexander
authors.initials: A
authors.lastname: Raufi
authors.affiliation: University of California Irvine, Division of Hematology-Oncology, Orange, CA, USA. Electronic address: sklempne@uci.edu.
authors.forename: Samuel J
authors.initials: SJ
authors.lastname: Klempner
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D055808:Drug Discovery; D018815:Genes, erbB / Q000502:physiology; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends; D040901:Proteomics / Q000379:methods; D015398:Signal Transduction / Q000235:genetics; D013274:Stomach Neoplasms / Q000628:therapy*
chemical_list: D020533:Angiogenesis Inhibitors
keywords: Cancer; Gastric; Mutation; Proteomics; Sequencing; Targeted therapy